HIVE vs HUT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 16, 2026

HIVE

46.3
AI Score
VS
HIVE Wins

HUT

42.6
AI Score

Investment Advisor Scores

HIVE

46score
Recommendation
HOLD

HUT

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HIVE HUT Winner
Revenue 79.12M 145.95M HUT
Net Income -142.91M -370.04M HIVE
Net Margin -180.6% -253.5% HIVE
ROE -33.8% -25.7% HUT
ROA -15.5% -3.7% HUT
Total Assets 924.64M 9.98B HUT
Cash 208.04M 233.58M HUT
Current Ratio 1.96 19.35 HUT

Relative Price Performance (Last 90 Days)

HIVE 1M: +7.4% · 3M: -27.0% HUT 1M: +1.9% · 3M: -27.5%

Current Technical Phase

HIVE

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -11.4%) with fading momentum, RSI 48

RSI (14): 47.9 · Price: $2.89

HUT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.5 · Price: $87.09

Fundamentals Snapshot

Metric HIVE HUT
Market Cap
Forward P/E -5.7 -16.8
Trailing P/E
Revenue (TTM)
Revenue Growth 0.7% 0.8%
Gross Margin 0.4% 0.6%
Operating Margin -0.6% -2.8%
EPS -1.39 -5.40
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.